SS-31 (Elamipretide): Mitochondrial Peptide Research Guide

SS-31 (elamipretide) is a synthetic, water-soluble tetrapeptide from the Szeto-Schiller peptide series. It carries an alternating aromatic-cationic sequence that lets it accumulate in the inner mitochondrial membrane, where it associates with the phospholipid cardiolipin. Research examines its effects on mitochondrial bioenergetics, membrane organization and oxidative stress across cardiac, renal, neurological and rare-disease models.

What SS-31 Is and Where It Came From

The Szeto-Schiller (SS) peptides emerged from work on opioid-peptide analogs, where researchers noticed that certain short aromatic-cationic sequences distributed into cells and concentrated inside mitochondria without requiring a membrane potential to get there. SS-31 became the most studied member of that family. Its clinical development name is elamipretide; older literature and vendor catalogs also list it as MTP-131 or Bendavia.

Structurally it is a four-residue peptide with an unusual alternating pattern of aromatic and basic side chains. That arrangement gives it a net positive charge and a hydrophobic face at the same time — the combination that drives its partitioning into the inner mitochondrial membrane, an anionic, cardiolipin-rich environment. Unlike triphenylphosphonium-conjugated mitochondrial agents, SS-31 does not depend on the mitochondrial membrane potential for uptake, which is one reason it has drawn attention in models where that potential is already collapsing.

A 2025 review in the International Journal of Molecular Sciences covers the structure, mechanism and therapeutic potential of elamipretide in depth, and a companion 2025 review in Biomedicine & Pharmacotherapy surveys contemporary insights into its mitochondrial mechanism. Those two papers are the natural starting point for anyone building background on the compound.

Reported Mechanism of Action

The dominant model in the literature is cardiolipin binding. Cardiolipin is a four-tailed phospholipid found almost exclusively in the inner mitochondrial membrane, where it helps shape cristae curvature, anchors cytochrome c, and supports the assembly of respiratory chain complexes into supercomplexes. When cardiolipin is depleted, remodeled abnormally, or peroxidized — as happens in ischemia, aging, and certain genetic conditions — cristae architecture and electron transport efficiency degrade together.

SS-31 is described as associating with cardiolipin-containing membranes and, in doing so, helping preserve that organization. Reported downstream consequences in experimental systems include improved electron flux, reduced electron leak and reactive oxygen species generation, better retention of cytochrome c, and preserved cristae morphology on electron microscopy. Importantly, the peptide is generally characterized as a membrane-interacting agent rather than a classical antioxidant scavenger.

Beyond cardiolipin: a genetically identified target

A 2024 genome-wide CRISPR screen published in the Journal of the American Society of Nephrology identified phospholipid scramblase 3 as a biological target of SS-31. Phospholipid scramblase 3 participates in cardiolipin trafficking between mitochondrial membranes, so the finding fits the lipid-centric picture while adding a defined protein node to it. It also gives the field something it had been missing: a genetic handle for testing mechanism rather than inferring it from phenotype alone.

Ferroptosis and cell-death pathways

More recent work has connected mitochondrial lipid protection to ferroptosis, the iron-dependent, lipid-peroxidation-driven form of cell death. A 2026 Neurotherapeutics paper reports that SS-31 improved post-cardiac-arrest brain injury in a model system by inhibiting microglial ferroptosis and shifting microglial polarization. A 2025 Biomedicine & Pharmacotherapy study describes a mitochondria-targeted SS-31 and ferrostatin-1 construct alleviating ferroptosis in hypoxia/reoxygenation cardiomyocytes. Both are early-stage findings, and the mechanistic link between membrane stabilization and ferroptosis suppression is still being worked out.

What the Research Literature Examines

The published work clusters into several areas. Across all of them, the honest summary is that preclinical signals have been more consistent than clinical translation, and that evidence remains preliminary outside of narrow indications.

Cardiac and ischemia-reperfusion research

Cardiac tissue has extraordinary mitochondrial density and cardiolipin content, which made it an obvious early target. Preclinical work in rodent and larger-animal models has examined infarct size, contractile recovery after reperfusion, and mitochondrial respiration in isolated cardiac fibers. The 2025 hypoxia/reoxygenation cardiomyocyte study noted above sits in this lineage. Clinical work in heart failure has been conducted, and results across trials have been mixed rather than uniformly positive — a point worth holding onto when reading enthusiastic secondary coverage.

Renal research

Kidney proximal tubules are similarly mitochondria-dense, and renal ischemia-reperfusion and chronic kidney injury models have generated a substantial body of SS-31 literature. The 2024 JASN CRISPR paper emerged from this space, which reflects how central nephrology research has been to mechanistic understanding of the peptide.

Rare mitochondrial disease

The most developed clinical dataset concerns Barth syndrome, a genetic disorder of cardiolipin remodeling caused by TAZ mutations. A 2024 report in Genetics in Medicine presented 168-week open-label extension results from the TAZPOWER study, describing long-term efficacy and safety observations in participants with Barth syndrome. A 2026 Drugs article titled "Elamipretide: First Approval" documents that elamipretide reached an initial regulatory approval — a meaningful milestone, and one that applies to a specific approved indication and formulation, not to the broad exploratory uses discussed across the research literature.

Neurological research

Neurons are metabolically demanding and vulnerable to mitochondrial failure, so models of ischemic brain injury, neurodegeneration and neuroinflammation have been explored. The 2026 post-cardiac-arrest brain injury work is the clearest recent example. This area remains early.

Aging, musculoskeletal and stem cell biology

A 2025 paper in Organogenesis reports that SS-31 targeted NOS2 to enhance osteogenic differentiation in aged bone marrow stromal cells by restoring mitochondrial function. Related lines of inquiry examine skeletal muscle bioenergetics and age-associated decline in mitochondrial capacity. These are cell and animal studies; extrapolation beyond them is not supported.

Laboratory Handling in General Terms

SS-31 is supplied as a lyophilized white powder under vacuum or inert gas. Handling practice mirrors that of other small hydrophilic peptides, and the details below are general laboratory conventions rather than protocol instructions.

• Receiving and storage of powder. Lyophilized material is typically kept cold and protected from light and moisture. Vials are usually allowed to reach room temperature before opening so condensation does not settle on the cake.
• Reconstitution. The peptide is readily water-soluble. Laboratories generally introduce sterile diluent slowly down the vial wall rather than directly onto the powder, then allow dissolution by gentle swirling. Vigorous shaking is avoided because mechanical shear and foaming can degrade peptides.
• Post-reconstitution storage. Solutions are typically refrigerated for short-term use. For longer intervals, aliquoting into single-use portions limits repeated freeze-thaw cycles, which are a common and avoidable source of potency loss.
• Documentation. Recording lot number, reconstitution date, diluent identity and concentration on the vial and in the lab notebook is what makes a result reproducible months later.

Companion articles on this site cover reconstitution math, storage timelines, and vial handling in step-by-step detail for laboratory personnel who need them.

Regulatory and Research-Use Status

This point deserves plain language. Elamipretide has been reported to receive a first regulatory approval in a defined clinical context, but SS-31 material distributed by research peptide suppliers is not an approved drug product, is not FDA-approved for any of the exploratory applications described in the literature above, and is not intended for human or veterinary use. It is supplied for laboratory research use only, by qualified personnel, in appropriate facilities, under applicable institutional oversight.

Nothing in the published literature summarized here should be read as a therapeutic claim. Preclinical findings in cells and animals frequently fail to reproduce in human trials, and elamipretide's own clinical history illustrates exactly that gap.

How Researchers Evaluate Supplier Quality

Peptide quality is the single largest uncontrolled variable in most independent research. A rigorous supplier makes that variable checkable.

1. Per-batch third-party COA. The certificate should correspond to the specific lot in hand, not a representative or historical batch, and should come from an independent analytical laboratory.
2. HPLC purity with a visible chromatogram. A purity percentage alone is weak evidence. The chromatogram shows peak shape, retention time and the size of nearby impurity peaks — information a single number hides.
3. Mass spectrometry identity. Purity confirms homogeneity; mass spec confirms the molecule is actually the intended tetrapeptide, with observed mass matching theoretical mass.
4. Batch traceability. Lot numbers printed on the vial that match the COA, with retained records, allow a researcher to trace an anomalous result back to material.
5. Supporting specifications. Depending on the application, laboratories may also look for water content, residual solvent, acetate content, and endotoxin data.

Real Peptides publishes COAs per batch for this reason: reproducibility begins with knowing precisely what was in the vial.

Where the Open Questions Are

Several genuine unknowns keep this compound interesting rather than settled.

• Target hierarchy. With cardiolipin binding and phospholipid scramblase 3 both implicated, the relative contribution of lipid interaction versus defined protein engagement is unresolved.
• Preclinical-to-clinical translation. Robust animal effects have not consistently reproduced in larger human studies, and the reasons — exposure, patient selection, endpoint choice, disease stage — are still debated.
• Which mitochondrial dysfunction responds. Genetic cardiolipin remodeling defects and acute ischemic injury are very different problems. It is not established which categories of mitochondrial impairment are actually addressable by a membrane-stabilizing peptide.
• Ferroptosis mechanism. The link between membrane stabilization and suppression of iron-dependent lipid peroxidation is newly described and not yet mechanistically complete.
• Biomarkers. The field still lacks a well-validated, accessible readout of target engagement, which complicates both preclinical design and clinical interpretation.

Researchers approaching SS-31 for the first time are generally best served by reading the 2025 mechanistic reviews first, then the CRISPR target paper, then the TAZPOWER extension — that sequence moves from mechanism to genetic validation to the most mature human dataset available.

Research-grade SS-31 (Elamipretide): Real Peptides supplies SS-31 (Elamipretide) for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore SS-31 (Elamipretide) research on Real Peptides

The articles below go deeper on the questions researchers ask most about SS-31 (Elamipretide).

Buying & quality

• SS-31 Cost Per Month Budget — Real Research Pricing
• SS-31 Alternatives 2026 Best — Mitochondrial Peptide Guide
• Best SS-31 for Heart Failure — Research Insights

Research questions

• SS-31 News 2026 — Latest Elamipretide Updates | Real
• SS-31 Oral Taste — What Researchers Report | Real Peptides

Research timelines & mechanisms

• How Long SS-31 Stays in System — Clearance Timeline
• SS-31 for Women — Mitochondrial Benefits | Real Peptides
• SS-31 Not Working? Reasons and Fixes | Real Peptides

Safety & side effects

• SS-31 Side Effects — What Researchers Need to Know
• Does SS-31 Cause Side Effects in Studies? Research Data

Reconstitution, storage & handling

• How Long SS-31 Vial Lasts — Storage, Potency & Use Timeline
• Does SS-31 Need Refrigeration? Storage Guide
• How to Mix SS-31 Calculator — Reconstitution Guide
• What Temperature Should SS-31 Be Stored At? (Stability

Stacks & comparisons

• SS-31 vs SS-LUP-332: Which Peptide Works Better?
• What Is SS31 Same as SS-31? (Mitochondrial Peptide
• SS-31 vs SS-LUP-332 — Mitochondrial Peptides Compared
• SS-31 Quality: Real Peptides vs Competitors | 2026 Analysis

Legal & regulatory

• Is SS-31 Legal? (Regulatory Status Explained)
• Is SS-31 Legal in 2026? (Regulatory Status & Research Use)

What Is the Difference Between SS-31 and Elamipretide on a Research Label?

SS-31 and elamipretide name the same tetrapeptide, D-Arg-2',6'-dimethyl-Tyr-Lys-Phe-NH2. "SS-31" is the laboratory designation from the Szeto–Schiller series of aromatic-cationic peptides developed in academic work during the early 2000s, where numbered compounds were screened for mitochondrial localization. "Elamipretide" is the International Nonproprietary Name adopted once the molecule entered formal clinical development, and the same material has also appeared in literature as MTP-131 and Bendavia. Because of that history, a vial labeled SS-31 and a vial labeled elamipretide should carry an identical molecular formula and monoisotopic mass; a supplier presenting them as chemically distinct entities is describing nomenclature, not chemistry. The practical differences lie in salt form (acetate versus trifluoroacetate), counterion content, and net peptide content stated on documentation, all of which change the mass of powder in a vial without changing identity. Researchers comparing listings usually confirm sequence and mass first, then review salt form. Further background on naming conventions appears in SS-31 vs elamipretide, a side-by-side comparison discussion, and the development history of the peptide. Sourcing considerations are covered under research-grade elamipretide.

How Is SS-31 Purity Verified Before a Vial Ships?

Purity verification for a short synthetic tetrapeptide rests on two orthogonal analyses. Reverse-phase HPLC separates the target peptide from deletion sequences, incomplete deprotection products, and oxidation byproducts; the chromatogram reports area percent at a stated wavelength, commonly 214 nm, where the amide backbone absorbs. Mass spectrometry, typically ESI-MS or MALDI-TOF, confirms that the dominant peak matches the expected molecular weight of the D-Arg-dimethylTyr-Lys-Phe-NH2 sequence rather than a near-isobaric impurity. A credible certificate of analysis pairs both traces with lot number, synthesis date, salt form, and net peptide content, and the lot number on the COA should match the vial label rather than being a generic document reused across batches. Some laboratories additionally request water content by Karl Fischer titration and residual solvent or counterion data, since trifluoroacetate carryover can influence cell-based readouts. Third-party testing from an independent analytical laboratory adds value precisely because it is not generated in-house. Evaluation frameworks are discussed in how to tell if a peptide supplier is legitimate, with compound-specific notes in research-grade SS-31 sourcing and handling lyophilized powder.

How Should Lyophilized SS-31 Be Stored in a Laboratory Setting?

Lyophilized peptide powders are generally the most stable form of a given compound, and SS-31 follows the same pattern as other short synthetic sequences. Freeze-dried material is typically held cold, sealed, protected from light, and kept dry, because residual moisture is the main driver of hydrolytic degradation in powder form. Cold-chain shipping is common but not universally required for short transit times, since lyophilized peptides tolerate brief ambient exposure better than solution-state material; suppliers usually state their own stability window on documentation. Repeated warming and cooling of a sealed vial encourages condensation inside the container, so laboratories often aliquot at the point of first opening rather than returning the same vial to cold storage repeatedly. The dimethyltyrosine residue contributes aromatic character to the molecule, and oxidative stress from prolonged light or air exposure is a recognized concern for tyrosine-containing peptides generally. Solution-state stability is a separate question governed by pH, temperature, and freeze-thaw history. Related discussion appears in lyophilized powder handling, factors affecting degradation and stability, and half-life considerations researchers track.

What Does the Cardiolipin-Binding Model Predict About SS-31 Selectivity?

The prevailing mechanistic model holds that SS-31 concentrates at the inner mitochondrial membrane through an interaction with cardiolipin, a four-chain phospholipid found almost exclusively in that membrane. The peptide's alternating cationic and aromatic residues allow electrostatic association with cardiolipin's anionic head groups plus hydrophobic insertion of aromatic side chains, which together explain selectivity for mitochondria over other organelles without dependence on a classical cell-surface receptor. Research reported by Birk and colleagues described SS-31 interacting with cardiolipin and affecting mitochondrial bioenergetics in ischemic tissue models (PubMed 23813215 (PubMed PMID 23813215)). A pharmacological review of the compound as a cardiolipin-protective agent sets out the broader framework (PubMed 24117165 (PubMed PMID 24117165)). Because cardiolipin organizes cristae architecture and supports supercomplex assembly among respiratory chain components, the model predicts effects on electron transport efficiency and electron leak rather than on a single enzyme target. This distinguishes SS-31 from agents designed to scavenge reactive species after they form. Mechanistic detail is expanded in cardiolipin binding research, how cardiolipin interaction protects mitochondria, and detailed mitochondrial targeting.

What Has the Elamipretide Clinical Research Program Examined?

Under the name elamipretide, the molecule has been studied in sponsored clinical programs across several indications tied to mitochondrial dysfunction. Published and registered work has addressed primary mitochondrial myopathy, Barth syndrome, heart failure with reduced ejection fraction, ischemia-reperfusion contexts, and ophthalmic conditions involving retinal pigment epithelium. These programs have produced a mixture of outcomes across phases, with some endpoints meeting prespecified criteria and others not, and regulatory review has at times requested additional confirmatory evidence. Researchers reading this literature generally distinguish between mechanistic endpoints, such as phosphocreatine recovery kinetics or mitochondrial respiration measures, and functional endpoints, such as walk-test performance, because the two have not always moved together. The clinical record also matters for laboratory work because it provides pharmacokinetic and tolerability context that purely preclinical datasets lack. None of this constitutes guidance for use outside controlled research. Summaries of the current landscape appear in clinical trials status, with indication-specific overviews in Barth syndrome research, heart failure investigation, and recent trial developments.

Is SS-31 Approved by the FDA or Legal to Obtain for Laboratory Work?

SS-31 is not an FDA-approved drug product. Elamipretide has progressed through investigational pathways, which means it has been studied under regulatory oversight, but investigational status is not approval and does not confer any authorization for use outside a sanctioned clinical study. Material sold as SS-31 by research suppliers is offered for in vitro and laboratory investigation only, labeled as not for human consumption, and is not manufactured to pharmaceutical standards unless explicitly documented otherwise. In the United States, the sale of such compounds for bona fide research sits apart from the regulatory framework governing drugs, dietary supplements, and compounded preparations, and marketing language that implies therapeutic benefit is what typically attracts enforcement attention. Institutional buyers generally document chain of custody, keep COAs on file, and ensure that material is logged under the appropriate laboratory inventory controls. Import rules, state-level provisions, and institutional policies may add further constraints. Current regulatory framing is discussed in FDA approval status for this research peptide, broader context in research peptide legality and FDA rules, and purchase considerations in legal purchase for research.

How Does SS-31 Compare With Other Mitochondria-Targeted Research Compounds?

Mitochondria-targeted research compounds fall into several structural classes with different logic. Triphenylphosphonium conjugates, such as mitoquinone and plastoquinone derivatives, accumulate by exploiting the inner membrane potential and carry an attached redox-active moiety. SS-31 differs in that its uptake is described as largely potential-independent, relying instead on cardiolipin association, which in principle means depolarized or damaged mitochondria remain accessible. A separate class comprises mitochondria-derived peptides such as MOTS-c and humanin, which are encoded within mitochondrial DNA and are studied as signaling molecules acting on nuclear transcriptional programs rather than as membrane-localizing agents. Classical antioxidants and NAD+ precursors represent yet another approach, addressing redox balance or cofactor availability instead of membrane architecture. These mechanisms are not interchangeable, and comparative preclinical data across them remains limited, so most laboratories treat them as complementary experimental tools rather than substitutes. Earlier work in the Szeto–Schiller series characterized cell-permeable peptide antioxidants targeted to the inner mitochondrial membrane (PubMed 15178689 (PubMed PMID 15178689)). Comparative overviews appear in mitochondrial peptide alternatives, SS-31 and MOTS-c research, and bioavailability and mitochondrial access.

What Readouts and Biomarkers Do Laboratories Track in SS-31 Studies?

Experimental work with SS-31 typically centers on bioenergetic and redox readouts rather than on a single assay. Common measures include oxygen consumption rate and extracellular acidification in respirometry platforms, ATP content, membrane potential assessed with fluorescent probes, and reactive oxygen species production quantified in isolated mitochondria or intact cells. Structural endpoints include cristae morphology by electron microscopy and cardiolipin composition profiled by lipidomic mass spectrometry, since remodeling of cardiolipin acyl chains is a recurring theme in mitochondrial dysfunction models. Transcriptomic approaches add expression panels covering mitochondrial biogenesis regulators, fission-fusion machinery, and antioxidant response elements. In vivo preclinical designs have also used 31P magnetic resonance spectroscopy to follow phosphocreatine recovery as a non-invasive proxy for oxidative capacity. Choice of readout matters because effects reported at the organelle level do not automatically translate to tissue-level function, and this gap is a frequent subject of discussion in the literature. Readout selection and interpretation are explored further in SS-31 biomarkers, downstream cellular effects, gene expression findings, and metabolism and energy research insights.

What Do Aging and Skeletal Muscle Models Investigate With SS-31?

Aging research interest in SS-31 stems from the observation that mitochondrial function declines with age in post-mitotic tissues such as skeletal muscle, heart, and kidney, and that cardiolipin content and acyl-chain composition shift in parallel. Preclinical models in aged rodents have been used to ask whether a cardiolipin-interacting peptide can alter oxidative capacity, electron leak, or muscle contractile performance, with endpoints including in vivo phosphocreatine recovery, fatigue resistance, and mitochondrial protein oxidation. Related studies examine exercise-adaptation contexts, where training itself alters mitochondrial density and the question becomes whether pharmacological targeting adds to or interacts with that adaptation. This body of work remains predominantly animal and cell based, and translation to clinical aging endpoints has not been established; findings are frequently model-specific, differing between tissue types and between acute injury and chronic aging paradigms. Researchers reviewing this area generally weight study design, species, and duration heavily when comparing reports. Overviews are collected in aging and mitochondrial peptide research, a broader aging guide, discussion of mitochondrial targeting in aging research, and exercise performance investigation.

Why Does Mitochondrial Dysfunction Research Keep Returning to This Peptide?

Mitochondrial dysfunction is implicated across cardiology, nephrology, neurology, and metabolic disease, but most intervention strategies have targeted downstream consequences such as accumulated oxidative damage. SS-31 attracted sustained attention because it proposes an upstream structural mechanism: stabilizing the lipid environment that organizes the electron transport chain, rather than mopping up radicals after electron leak occurs. That framing makes it useful as a mechanistic probe. If a disease model responds to cardiolipin-directed intervention, it suggests inner-membrane organization is part of the pathology; if it does not, investigators can rule that pathway out. The compound has therefore appeared in ischemia-reperfusion studies, genetic mitochondrial disease models, cardiac remodeling work, and renal injury research, each asking a somewhat different question. The breadth of this literature is a strength for hypothesis generation and a weakness for synthesis, since heterogeneous models and endpoints resist direct comparison. Reviews and critical appraisals both note that mechanism-level effects have been more consistently reproduced than functional ones. Further reading includes mitochondrial dysfunction research and mechanism, mitochondrial function research, cellular energy mechanism research, and mitochondrial disease investigation.

References

Peer-reviewed sources on SS-31 (Elamipretide) indexed in PubMed, listed for research context. Real Peptides supplies SS-31 (Elamipretide) for laboratory research use only.

1. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. International journal of molecular sciences, 2025. PMID 39940712. doi:10.3390/ijms26030944
2. Elamipretide: First Approval. Drugs, 2026. PMID 41335372. doi:10.1007/s40265-025-02269-8
3. SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. PMID 41136322. doi:10.1016/j.neurot.2025.e00772
4. SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 39848110. doi:10.1016/j.biopha.2025.117832
5. Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2025. PMID 40294492. doi:10.1016/j.biopha.2025.118056
6. SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function. Organogenesis, 2025. PMID 40570323. doi:10.1080/15476278.2025.2519649
7. Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31. Journal of the American Society of Nephrology : JASN, 2024. PMID 38530359. doi:10.1681/ASN.0000000000000338
8. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in medicine : official journal of the American College of Medical Genetics, 2024. PMID 38602181. doi:10.1016/j.gim.2024.101138